Sept. 17, 2020
The National Institutes of Health has awarded Xunlei Kang, an assistant professor at the University of Missouri School of Medicine, a $1.7 million grant to study whether a drug used to treat Type 2 diabetes can prevent acute myeloid leukemia (AML) from spreading throughout the body.
AML accounts for more than 40% of leukemia-related deaths in the U.S., and most people with the disease die within a few years of diagnosis. Despite the numbers, Kang said there has not been progress in treatment in 40 years because targeting the diseased cells is difficult.
Kang and his team will use a Type 2 diabetes drug to try and delay — or even reverse — AML by targeting only the diseased myeloid stem cells and restraining them inside the bone marrow, which would stop them from entering the bloodstream and invading lymph nodes and other organs.
Three MU faculty named Fellows of the American Association for the Advancement of Science
Former UM System president gives $2 million to NextGen Data Science and Analytics Innovation Center at UMKC
Gift supports a collaborative effort between UMKC and MU housed in Kansas City.
UM System announces strategic investments to advance humanities, fine arts, social and behavioral sciences research initiatives at MU
MU research project to study COVID-19 immunity
Blood draws will detect COVID-19 antibody presence over time.
Stay up-to-date on all things Mizzou when you subscribe to the Show Me Mizzou newsletter. Issues will arrive in your inbox every Tuesday, Wednesday and Thursday.